Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Conditions

• Intracerebral Hemorrhage

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Intravenous nicardipine hydrochloride — DRUG
  IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range. Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.

Study Details

The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset. 2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months. 3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans. 4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.

Key Dates

Start date

May 15, 2011

Status verified

Mar 2017

Primary completion

Dec 21, 2015

Completion

Mar 8, 2016

Study Design

Enrollment

1,000 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Standard SBP Reduction Arm
  Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or "PRN") as the primary agent in lowering SBP. The goal for the standard BP reduction group will be to reduce and maintain SBP \< 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm. For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ.
• Active Comparator: Intensive SBP Reduction Arm
  Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or "PRN") as the primary agent in lowering SBP. The goal for the intensive BP reduction group will be to reduce and maintain SBP \< 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm. For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ.

Primary Outcome Measure

Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization [ Time Frame: 90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization ]

Locations (116)

Find similar trials in Birmingham, AL

Related Studies

• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
  PHASE3 · Recruiting · Yale University · Birmingham, Alabama
• Statins In Intracerbral Hemorrhage
  PHASE3 · Recruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
• Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
  Recruiting · Massachusetts General Hospital · Phoenix, Arizona
• Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?
  PHASE1 · Recruiting · Montefiore Medical Center · The Bronx, New York